Phaseline

Companies › Suninflam

Suninflam: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SIF001
Monoclonal antibody with potential to treat epilepsy
–Phase 1EpilepsyJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07051629SIF001Phase 1EpilepsyNeurologyJan 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.